Skip to main content

Table 2 Results of logistic regression model based on different biomarker panels

From: UPLC-MS based urine untargeted metabolomic analyses to differentiate bladder cancer from renal cell carcinoma

Groups

AUC

Sensitivity

Specificity

1Cancers(BC&RCC) vs controls

 discovery group

0.950(0.942–0.958)

0.868(0.846–0.891)

0.875(0.855–0.895)

 10-fold cross-validation

0.933(0.902–0.925)

0.857(0.857–0.926)

0.880(0.822–0.939)

2BC vs RCC without hematuria

 discovery group

0.829(0.802–0.855)

0.832(0.801–0.862)

0.706(0.666–0.747)

 10-fold cross-validation

0.784(0.695–0.874)

0.802(0.802–0.908)

0.698(0.575–0.822)

3BC vs RCC with hematuria

 discovery group

0.913(0.885–0.942)

0.847(0.795–0.898)

0.953(0.937–0.970)

 10-fold cross-validation

0.870(0.754–0.986)

0.857(0.857–1.00)

0.913(0.847–0.980)

  1. 1The biomarker panel: α-CEHC, β-cortolone, deoxyinosine, flunisolide, 11b,17a,21-trihydroxypreg-nenolone and glycerol tripropanoate
  2. 2The biomarker panel: 4-ethoxymethylphenol, prostaglandin F2b, thromboxane B3, hydroxybutyrylcarnitine, 3-hydroxyphloretin and N′-formylkynurenine
  3. 3The biomarker panel: 1-hydroxy-2-oxopropyl tetrahydropterin, 1-acetoxy-2-hydroxy-16-heptadecyn-4-one, 1,2-dehydrosalsolinol and L-tyrosine